Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN…

Overview of attention for article published in The Journal of Headache and Pain, October 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (85th percentile)
Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

news: 1 news outlet
policy: 1 policy source

twitter: 1 X user

Citations

dimensions_citation: 14 Dimensions

Readers on

mendeley: 48 Mendeley

Summary News Policy documents X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 1,651 followers.

Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials) https://t.co/rAPm2hbAS3

18 Oct 2020

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.